PCSK9 inhibitors combined with atorvastatin/rosuvastatin
1100939
Phase 3 small_molecule active
Quick answer
PCSK9 inhibitors combined with atorvastatin/rosuvastatin for Acute Ischemic Stroke is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Acute Ischemic Stroke
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active